Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for solid tumor cancers. With a mission to create safer and more effective cancer treatments, Intensity Therapeutics utilizes its proprietary DfuseRxSM technology platform to formulate novel drugs designed for direct injection into tumors. This approach allows therapeutic agents to rapidly disperse throughout the tumor, targeting cancer cells directly.

Based in Shelton, Connecticut, Intensity Therapeutics' lead product candidate, INT230-6, is currently undergoing Phase 1/2 clinical trials in patients with advanced solid tumors. INT230-6 has shown promise in inducing an adaptive immune response that can attack not only the injected tumor but also non-injected tumors and unseen micro-metastases. Intensity Therapeutics is dedicated to advancing cancer care through groundbreaking research and development. You can find Intensity Therapeutics, Inc. at 1 Enterprise Dr Suite 430, Shelton, Connecticut 06484, US, with an additional location at 61 Wilton Road, 3rd Floor, Westport, CT 06880, US.

Intensity Therapeutics, Inc. is committed to pushing the boundaries of cancer treatment and improving patient outcomes. The company's innovative approach and dedication to research make it a key player in the biopharmaceutical industry. We encourage the management team at Intensity Therapeutics, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their achievements and drive commercial development.